Please assess the completion status of the following clinical trial:

Trial Title: Preventing Recurrent Urinary Tract Infections With α-D-mannose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women~* ≥ 3 UTIs within the last 12 months or ≥ 2 UTIs within the last 6 months;~* Laboratory urine culture: \<103 CFUs~* Age \> 18 years~Exclusion Criteria:~* UTIs ≥ 12 within 1 year~* Pregnancy or Lactation~* Immune disease~* Lactose intolerance~* Urinary tract anomaly~* Systemic infection~* Newly started hormone therapy within the last 6 months~* Antibiotic prophylaxis within the last 6 months~* α-D-mannose intake within the last month~* Use of catheters~* Diabetes mellitus~* Participation to other studies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mannose (Type: EXPERIMENTAL): 2g d-mannose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months.The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary
- placebo (Type: PLACEBO_COMPARATOR): 2g Hänseler lactose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months. The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary

Based on this trial design, predict the completion outcome and termination type (if applicable).